{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:09Z","timestamp":1790686209412,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00277-019-03837-1","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T06:01:56Z","timestamp":1574056916000},"page":"2847-2849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7704-4728","authenticated-orcid":false,"given":"Anna Maria","family":"Peri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Rossio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tafuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Benzecry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"issue":"1","key":"3837_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/cid\/cix687","volume":"66","author":"G Chamilos","year":"2018","unstructured":"Chamilos G, Lionakis MS, Kontoyiannis DP (2018) Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. Clin Infect Dis 66(1):140\u2013148","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3837_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.idc.2015.10.006","volume":"30","author":"EK Maziarz","year":"2016","unstructured":"Maziarz EK, Perfect JR (2016) Cryptococcosis. Infect Dis Clin N Am 30(1):179\u2013206","journal-title":"Infect Dis Clin N Am"},{"issue":"3","key":"3837_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/345956","volume":"36","author":"S Neuville","year":"2003","unstructured":"Neuville S, Dromer F, Morin O, Dupont B, Ronin O (2003) Lortholary O; French Cryptococcosis Study Group. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 36(3):337\u2013347","journal-title":"Clin Infect Dis"},{"key":"3837_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3109\/10428194.2012.717081","volume":"54","author":"T Marchand","year":"2013","unstructured":"Marchand T, Revest M, Tattevin P, Chevrier S, Poullot E, Lamy T, Houot R (2013) Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia. Leuk Lymphoma 54:643\u2013645","journal-title":"Leuk Lymphoma"},{"key":"3837_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1179\/joc.2009.21.2.211","volume":"21","author":"M Bassetti","year":"2009","unstructured":"Bassetti M, Repetto E, Mikulska M, Miglino M, Clavio M, Gobbi M, Righi E, Viscoli C (2009) Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother 21:211\u2013214","journal-title":"J Chemother"},{"issue":"2","key":"3837_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/039463200802100227","volume":"21","author":"V Devirgiliis","year":"2008","unstructured":"Devirgiliis V, Panasiti V, Borroni RG, Rossi M, Curzio M, Riggio R, Fioriti D, Nicosia R, Pietropaolo V, Tecca M, Chiarini F, Innocenzi D, Calvieri S (2008) Cutaneous cryptococcosis in a patient affected by chronic lymphocytic leukaemia: a case report. Int J Immunopathol Pharmacol 21(2):463\u2013466","journal-title":"Int J Immunopathol Pharmacol"},{"key":"3837_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-015-0157-x","volume":"8","author":"R Maffei","year":"2015","unstructured":"Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R (2015) Targeting neoplastic B cells and harnessing microenvironment: the \"double face\" of ibrutinib and idelalisib. J Hematol Oncol 8:60","journal-title":"J Hematol Oncol"},{"issue":"15","key":"3837_CR8","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubowsky","year":"2013","unstructured":"Dubowsky JA, Beckwith KA, Natarajan G et al (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122(15):2539\u20132549","journal-title":"Blood"},{"issue":"4","key":"3837_CR9","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2010-04-281170","volume":"117","author":"K Fiedler","year":"2011","unstructured":"Fiedler K, Sindrilaru A, Terszowski G, Kokai E, Feyerabend TB, Bullinger L, Rodewald HR, Brunner C (2011) Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood. 117(4):1329\u20131339","journal-title":"Blood."},{"issue":"4","key":"3837_CR10","doi-asserted-by":"publisher","first-page":"e00265","DOI":"10.1128\/mBio.00265-13","volume":"4","author":"WA Szymczak","year":"2013","unstructured":"Szymczak WA, Davis MJ, Lundy SK, Dufaud C, Olszewski M, Pirofski LA (2013) X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans infection. MBio 4(4):e00265\u2013e00213","journal-title":"MBio"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03837-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03837-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:15:10Z","timestamp":1605572110000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03837-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3837"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03837-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,18]]},"assertion":[{"value":"26 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AB has received personal fees including consultancy and travel grants from Gilead Sciences, Janssen Pharmaceuticals, ViiV Healthcare, Merck Sharp & Dohme, Nordic Pharma, Pfizer, and AbbVie. She has also received research grants from Gilead Sciences. FP has received honoraria for participating as a speaker at satellite symposia and educational meetings organized by Bioverativ, CSL Behring, Grifols, Novo Nordisk, Roche, Sanofi, Sobi, Spark Therapeutics, Sysmex, and Takeda. She is also member of the scientific advisory board of Sanofi. Other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable since the paper does not contain any studies performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication of their clinical details and clinical images was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}